Nasdaq

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023

The loss of insulin-producing beta cells is a root biological cause of type 2 diabetes and its progression. BMF-219, a novel covalent menin inhibitor, is designed to potentially regenerate, preserve, ...
Seeking Alpha

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to ...
Nasdaq

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

The clinical study, COVALENT-112, has initiated enrollment of adults living with type 1 diabetes in the US and Canada. Eligible patients include those who have been diagnosed with type 1 diabetes for ...
Seeking Alpha

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions ...

New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific Sessions Biomea to hold an investor and KOL event during the Scientific Sessions ...